BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Proximagen Neuroscience plc (PRX.L) Release: Interim Results For The Six Months Ended 31 May 2010


7/28/2010 10:37:34 AM

London, UK, 28 July 2010 – Proximagen Group plc (AIM: PRX), the biotechnology company focused on diseases of the central nervous system, is pleased to announce its interim results for the six months ended 31 May 2010.

Highlights:

• Acquisition of Minster Pharmaceuticals plc completed. • Positive results announced following NIH assessment of tonabersat for epilepsy. • Out-licensing agreement signed with Upsher-Smith Laboratories, Inc. for US rights to tonabersat with Proximagen retaining EU rights and a 50% share of Rest of the World rights. • Appointment of Dr Jackie Hunter as a non-executive director. Jackie is formerly the Vice President and Head of the Neurology & GI Centre of Excellence for Drug Discovery at GlaxoSmithKline. • Management team strengthened with the appointment of Dr Stevo Knezevic, formerly Chief Medical Officer (EMEA) at Wyeth, as Head of Development. • Continued strong R&D investment of £2.5 million in the period (period to 31 May 2009: £1.2 million). • Cash and other financial assets of £51.0 million at 31 May 2010 (30 November 2009: £55.6 million).

Post period-end highlights:

• Agreement signed with the NIH for the NIH to fund a Phase II proof of concept study on naluzotan assessing its efficacy in epilepsy.

Commenting on this announcement, Kenneth Mulvany, Chief Executive Officer of Proximagen Group plc, said: “The Company has made good progress in the first half of the year and we remain excited about prospects for the rest of 2010. Already in the second half we have signed an agreement with the NIH to fund a Phase II proof of concept study on naluzotan. This deal is a good example of our risk-mitigated approach to drug development. Strategic acquisitions and partnerships will continue to play a key role in our development and building a strong pipeline is our number one focus and priority as a company.”

For further information, please contact:

Proximagen Group plc Tel: 020 7400 7700 Kenneth Mulvany, Chief Executive Officer James Hunter, Finance Director

Pelham Bell Pottinger Tel: 020 7861 3800 Dan de Belder, Zoë Pocock

Evolution Securities Limited (NOMAD) Tel: 020 7071 4300 Bobbie Hilliam, Stuart Andrews

Malika Shermatova Account Executive

Direct line: +44(0)20 7861 3890 Mobile: +44 (0)7979 852 604

Pelham Bell Pottinger 5th Floor, Holborn Gate, 330 High Holborn, London, WC1V 7QD Tel: +44 (0)20 7861 3232 Fax: +44 (0)20 7861 3233 www.pelhambellpottinger.co.uk



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES